skip to Main Content

IntraBio is a global leader in developing therapies and treatments for rare and common neurodegenerative diseases, including lysosomal storage disorders, which have high unmet clinical needs.

IntraBio’s lead drug candidate was recently granted Orphan Drug Designation by the European Medicines Agency (EMA) for the treatment of Niemann-Pick Disease Types A, B & C. Pivotal trials are planned for late 2017/early 2018.

Press Release

Back To Top